Screening adults for bladder cancer: A review of the evidence for the U.S. Preventive Services Task Force

Annals of Internal Medicine

Volumn 153, Issue 7, 2010, Pages 461-468

  Chou, Roger ^a   Dana, Tracy ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ARTICLE; BLADDER CANCER; CANCER RESEARCH; CANCER SCREENING; COCHRANE LIBRARY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FOLLOW UP; HEMATURIA; HIGH RISK POPULATION; HUMAN; MEDLINE; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PREVENTIVE HEALTH SERVICE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; URINE CYTOLOGY; ADULT; BLADDER TUMOR; CYTOLOGY; EVIDENCE BASED MEDICINE; MASS SCREENING; REPRODUCIBILITY; REVIEW; RISK ASSESSMENT; STANDARD; URINALYSIS; URINE;

ADULT; EVIDENCE-BASED MEDICINE; HEMATURIA; HUMANS; MASS SCREENING; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL; URINALYSIS; URINARY BLADDER NEOPLASMS; URINE;

EID: 78349283393     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-153-7-201010050-00009     Document Type: Article

References (38)

1. U.S. Cancer Statistics Working Group. U.S. Cancer Statistics: 1999-2005. Incidence and Mortality Web-based Report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2009. Accessed at www.cdc.gov/uscs on 14 December 2009.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-49. [PMID: 19474385]
3. Kiemeney LA. Hereditary bladder cancer. Scand J Urol Nephrol Suppl. 2008:110-5. [PMID: 18815925]
4. Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005;66:4-34. [PMID: 16399414]
5. Olfert SM, Felknor SA, Delclos GL. An updated review of the literature: risk factors for bladder cancer with focus on occupational exposures. South Med J. 2006;99:1256-63. [PMID: 17195421]
6. Wu X, Ros MM, Gu J, Kiemeney L. Epidemiology and genetic susceptibility to bladder cancer. BJU Int. 2008;102:1207-15. [PMID: 19035883]
7. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009;374:239-49. [PMID: 19520422]
8. National Cancer Institute; U.S. National Institutes of Health. Bladder cancer treatment. General information about bladder cancer. Accessed at www.cancer.gov/cancertopics/pdq/treatment/bladder on 14 December 2009.
9. Pashos CL, Botteman MF, Laskin BL, Redaelli A. Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract. 2002;10:311-22. [PMID: 12406054]
10. American Cancer Society. Bladder cancer detailed guide. Accessed at www.cancer.org/docroot/CRI/CRI-2-3x.asp?dt=44 on 14 December 2009.
11. American Joint Committee on Cancer. What is cancer staging? 2009. Accessed at www.cancerstaging.org/mission/whatis.html on 14 December 2009.
12. Konety BR, Joyce GF, Wise F. Bladder and upper tract urothelial cancer. In: Litwin MS, Saigal. CS, eds. Urologic Diseases in America. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington, DC: U.S. Government Printing Office; 2007. NIH publication no. 07-5512.
13. Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007;178:2314-30. [PMID: 17993339]
14. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 1998;22:1435-48. [PMID: 9850170]
15. Madeb R, Golijanin D, Knopf J, Messing EM. Current state of screening for bladder cancer. Expert Rev Anticancer Ther. 2007;7:981-7. [PMID: 17627458]
16. RTI International-University of North Carolina Evidence-based Practice Center. Screening for Bladder Cancer. Brief Evidence Update (Prepared by RTI International-University of North Carolina Evidence-based Practice Center for the U.S. Preventive Services Task Force. Agency for Healthcare Research and Quality.) Rockville, MD: Agency for Healthcare Research and Quality; 2004. Accessed at www.uspreventiveservicestaskforce.org/3rduspstf/bladder/blacanup.htm on 18 August 2010.
17. National Cancer Institute. SEER Cancer Statistics Review 1975-2007. Accessed at http://seer.cancer.gov/csr/1975-2007/results-merged/sect-27-urinary- bladder.pdf on 30 April 2010.
18. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, et al; Methods Work Group, Third US Preventive Services Task Force. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20:21-35. [PMID: 11306229]
19. Leeflang MM, Deeks JJ, Gatsonis C, Bossuyt PM; Cochrane Diagnostic Test Accuracy Working Group. Systematic reviews of diagnostic test accuracy. Ann Intern Med. 2008;149:889-97. [PMID: 19075208]
20. Messing EM, Young TB, Hunt VB, Gilchrist KW, Newton MA, Bram LL, et al. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology. 1995;45:387-96. [PMID: 7879333]
21. Friedman GD, Hiatt RA, Quesenberry CP Jr, Selby JV, Weiss NS. Problems in assessing screening experience in observational studies of screening efficacy: example of urinalysis screening for bladder cancer. J Med Screen. 1995;2: 219-23. [PMID: 8719152]
22. Messing EM, Madeb R, Young T, Gilchrist KW, Bram L, Greenberg EB, et al. Long-term outcome of hematuria home screening for bladder cancer in men. Cancer. 2006;107:2173-9. [PMID: 17029275]
23. Thériault GP, Tremblay CG, Armstrong BG. Bladder cancer screening among primary aluminum production workers in Quebec. J Occup Med. 1990;32:869-72. [PMID: 2074510]
24. Hedelin H, Jonsson K, Salomonsson K, Boman H. Screening for bladder tumours in men aged 60-70 years with a bladder tumour marker (UBC) and dipstick-detected haematuria using both white-light and fluorescence cystoscopy. Scand J Urol Nephrol. 2006;40:26-30. [PMID: 16452052]
25. Whelan P, Britton JP, Dowell AC. Three-year follow-up of bladder tumours found on screening. Br J Urol. 1993;72:893-6. [PMID: 8306152]
26. Steiner H, Bergmeister M, Verdorfer I, Granig T, Mikuz G, Bartsch G, et al. Early results of bladder-cancer screening in a high-risk population of heavy smokers. BJU Int. 2008;102:291-6. [PMID: 18336612]
27. Lotan Y, Elias K, Svatek RS, Bagrodia A, Nuss G, Moran B, et al. Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker. J Urol. 2009;182:52-7. [PMID: 19450825]
28. Marsh GM, Cassidy LD. The Drake Health Registry Study: findings from fifteen years of continuous bladder cancer screening. Am J Ind Med. 2003;43:142-8. [PMID: 12541268]
29. Grossman HB, Messing E, Soloway M, Tomera K, Katz G, Berger Y, et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA. 2005;293:810-6. [PMID: 15713770]
30. Ponsky LE, Sharma S, Pandrangi L, Kedia S, Nelson D, Agarwal A, et al. Screening and monitoring for bladder cancer: refining the use of NMP22. J Urol. 2001;166:75-8. [PMID: 11435827]
31. Zippe C, Pandrangi L, Agarwal A. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer. J Urol. 1999;161:62-5. [PMID: 10037369]
32. Lotan Y, Capitanio U, Shariat SF, Hutterer GC, Karakiewicz PI. Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection. BJU Int. 2009;103:1368-74. [PMID: 19338566]
33. Britton JP, Dowell AC, Whelan P. Dipstick haematuria and bladder cancer in men over 60: results of a community study. BMJ. 1989;299:1010-2. [PMID: 2511941]
34. Aaronson DS, Walsh TJ, Smith JF, Davies BJ, Hsieh MH, Konety BR. Meta-analysis: does lidocaine gel before flexible cystoscopy provide pain relief? BJU Int. 2009;104:506-9. [PMID: 19239453]
35. Burke DM, Shackley DC, O'Reilly PH. The community-based morbidity of flexible cystoscopy. BJU Int. 2002;89:347-9. [PMID: 11872022]
36. Stav K, Leibovici D, Goren E, Livshitz A, Siegel YI, Lindner A, et al. Adverse effects of cystoscopy and its impact on patients' quality of life and sexual performance. Isr Med Assoc J. 2004;6:474-8. [PMID: 15326827]
37. Turan H, Balci U, Erdinc FS, Tulek N, Germiyanoglu C. Bacteriuria, pyuria and bacteremia frequency following outpatient cystoscopy. Int J Urol. 2006;13:25-8. [PMID: 16448428]
38. Collado A, Chéchile GE, Salvador J, Vicente J. Early complications of endoscopic treatment for superficial bladder tumors. J Urol. 2000;164:1529-32. [PMID: 11025697]